|Application ||WB, IHC-P, IF, E|
|Other Accession||NP_775262, 27894310|
|Calculated MW||Predicted: 17 kDa |
Observed: 27 kDa
|Application Notes||IL-36RN antibody can be used for detection of IL-36RN by Western blot at 1 - 2 µg/ml.|
|Target/Specificity||IL36RN; IL-36RN antibody is human specific. At least two isoforms of IL-36RN are known to exist|
|Reconstitution & Storage||IL-36RN antibody can be stored at 4℃ for three months and -20℃, stable for up to one year.|
|Precautions||IL-36RN Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Synonyms||FIL1D, IL1F5, IL1HY1, IL1L1, IL1RP3|
|Function||Inhibits the activity of interleukin-36 (IL36A,IL36B and IL36G) by binding to receptor IL1RL2 and preventing its association with the coreceptor IL1RAP for signaling. Part of the IL-36 signaling system that is thought to be present in epithelial barriers and to take part in local inflammatory response; similar to the IL-1 system with which it shares the coreceptor. Proposed to play a role in skin inflammation. May be involved in the innate immune response to fungal pathogens, such as Aspergillus fumigatus. May activate an anti-inflammatory signaling pathway by recruiting SIGIRR.|
|Tissue Location||Predominantly expressed in skin keratinocytes but not in fibroblasts, endothelial cells or melanocytes. Detected also in the spleen, brain leukocyte and macrophage cell types Increased in lesional psoriasis skin|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
IL-36RN is is a member of the interleukin 1 cytokine family whose gene and eight other interleukin 1 family genes form a cytokine gene cluster on chromosome 2 (1). IL-36RN specifically inhibits the activation of NF-kappaB induced IL-36A (2). The opposing activities of these cytokines have been suggested to be involved in the regulation of skin inflammation (3). Like the IL-36 cytokines (IL-36A, IL-36B and IL-36G), IL-36RN requires post-translational processing for full agonist activity, but the cleavage mechanism is currently unknown (4).
Smith DE, Renshaw BR, Ketchem RR, et al. Four new members expand the interleukin-1 superfamily. J. Biol. Chem. 2000; 275:1169-75.
Debets R, Timans JC, Homey B, et al. Two novel IL-1 family members, IL-1 delta and IL-1 epsilon, function as an antagonist and agonist of NF-kappa B activation through the orphan IL-1 receptor-related protein 2. J. Immunol. 2001; 167:1440-6.
Blumberg H, Dinh H, Trueblood ES, et al. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J. Exp. Med. 2007; 204:2603-14.
Towne JE, Renshaw BR, Douangpanya J, et al. Interleukin-36 (IL-36) ligands require processing for full agonist agonist (IL-36a, IL-36b, and IL-36g) or antagonist (IL-36Ra) activity. J. Biol. Chem. 2011; 286:42594-602.
If you have any additional inquiries please email technical services at email@example.com.